건선 환자에서 발생한 간질성 폐질환 1예 = A case of Interstitial Lung Disease in a Patient with Psoriasis

다국어 초록 (Multilingual Abstract)

Patients with psoriasis may be accompanied by various systemic comorbidities, including lung diseases, and it is crucial to manage them. Interstitial lung disease is occasionally reported in patients with psoriasis secondary to the use of immunosuppressants in most cases. A 54-year-old woman, who had a history of psoriasis for 2 years but had never used immunosuppressant or biologics, presented with cough and dyspnea that started 6 months ago. She was diagnosed with interstitial lung disease on chest X-ray and chest CT, and oral steroid was used. The interstitial lung disease responded to oral steroid treatment for one year, but psoriasis lesions became worse after discontinuing oral steroids.
She is currently being treated with narrowband ultraviolet B (NBUVB) therapy and calcipotriol/betamethasone topical gel. Herein, we report a rare case of interstitial lung disease in psoriasis patient.

참고문헌 (Reference)

1 이숙영 ; 문화식 ; 김관형 ; 박성학 ; 김완욱 ; 김석찬 ; 송정섭 ; 박찬석 ; 이상학 ; 심건호, "류마티스 관절염 환자에서 Methotrexate에 의해 발생한 간질성 폐렴 1예" 대한결핵및호흡기학회 57 (57): 273-277, 2004

2 박승배 ; 이증훈 ; 김형래 ; 임명 ; 이영 ; 서영준, "건선환자의 Etanercept (EnbrelⓇ) 치료 중 발생한 간질성 폐 질환" 대한피부과학회 51 (51): 709-712, 2013

3 Nie YJ, "Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis" 9 : 21-, 2022

4 Yamazaki F, "Psoriasis: Comorbidities" 48 : 732-740, 2021

5 Ungprasert P, "Psoriasis and risk of incident chronic kidney disease and end-stage renal disease : a systematic review and meta-analysis" 50 : 1277-1283, 2018

6 Griffiths CEM, "Psoriasis" 397 : 1301-1315, 2021

7 Zhang J, "Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease" 316 (316): L487-L497, 2019

8 Wijsenbeek M, "Interstitial lung diseases" 400 : 769-786, 2022

9 Perez-Alvarez R, "Interstitial lung disease induced or exacerbated by TNF-targeted therapies : analysis of 122 cases" 41 : 256-264, 2011

10 Whittington HA, "Interleukin-22 : a potential immunomodulatory molecule in the lung" 31 : 220-226, 2004

11 Olewicz-Gawlik A, "Interleukin-17 and interleukin-23 : importance in the pathogenesis of lung impairment in patients with systemic sclerosis" 17 : 664-670, 2014

12 Choi YM, "Incidence of Pulmonary Arterial Hypertension in Patients with Psoriasis : A Retrospective Cohort Study" 21 : 16-073, 2017

13 Molet S, "IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines" 108 : 430-438, 2001

14 Ishikawa G, "Concomitant Interstitial Lung Disease with Psoriasis" 2019 : 5919304-, 2019

15 Mleczko M, "Chronic Inflammation as the Underlying Mechanism of the Development of Lung Diseases in Psoriasis : A Systematic Review" 23 : 1767-, 2022

16 Miyagawa H, "Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis" 16 : e0245284-, 2021

17 Fu Y, "Association of Psoriasis With Inflammatory Bowel Disease : A Systematic Review and Meta-analysis" 154 : 1417-1423, 2018

18 Ungprasert P, "Association between psoriasis and chronic obstructive pulmonary disease : A systematic review and meta-analysis" 27 : 316-321, 2016

19 Wang J, "Association between psoriasis and asthma risk : A meta-analysis" 39 : 103-109, 2018

20 Li X, "Association between Psoriasis and Chronic Obstructive Pulmonary Disease : A Systematic Review and Meta-analysis" 10 : e0145221-, 2015